{
  "dimensions": [
    { "id": "time", "name": "Time", "kind": "datetime" },
    { "id": "company", "name": "Company", "kind": "categorical" },
    { "id": "eventType", "name": "Event Type", "kind": "categorical" },
    { "id": "score", "name": "Score", "kind": "numeric" },
    { "id": "source", "name": "Source", "kind": "categorical" },
    { "id": "impact", "name": "Impact", "kind": "numeric" }
  ],
  "nodes": [
    {
      "id": "node-001",
      "label": "TNXP – FastTrack granted",
      "dimensions": {
        "time": "2024-11-05",
        "company": "TNXP",
        "eventType": "FastTrack",
        "score": 0.86,
        "source": "FDA",
        "impact": 78
      }
    },
    {
      "id": "node-002",
      "label": "TNXP – Phase 3 interim data",
      "dimensions": {
        "time": "2025-02-14",
        "company": "TNXP",
        "eventType": "Phase 3 readout",
        "score": 0.74,
        "source": "Company PR",
        "impact": 65
      }
    },
    {
      "id": "node-003",
      "label": "TNXP – Financing round closed",
      "dimensions": {
        "time": "2025-05-08",
        "company": "TNXP",
        "eventType": "Financing",
        "score": 0.58,
        "source": "PR Newswire",
        "impact": 52
      }
    },
    {
      "id": "node-004",
      "label": "TNXP – Manufacturing audit delayed",
      "dimensions": {
        "time": "2025-07-19",
        "company": "TNXP",
        "eventType": "Regulatory",
        "score": null,
        "source": "Company PR",
        "impact": 40
      }
    },
    {
      "id": "node-005",
      "label": "TNXP – Global partnership announced",
      "dimensions": {
        "time": "2025-09-22",
        "company": "TNXP",
        "eventType": "Partnership",
        "score": 0.69,
        "source": "Business Wire",
        "impact": 72
      }
    },
    {
      "id": "node-006",
      "label": "TNXP – Phase 2 biomarker update",
      "dimensions": {
        "time": "2026-01-16",
        "company": "TNXP",
        "eventType": "Phase 2 readout",
        "score": 0.63,
        "source": "Investor Deck",
        "impact": 55
      }
    },
    {
      "id": "node-007",
      "label": "ABCL – Regulatory submission accepted",
      "dimensions": {
        "time": "2024-10-18",
        "company": "ABCL",
        "eventType": "Regulatory",
        "score": 0.79,
        "source": "FDA",
        "impact": 70
      }
    },
    {
      "id": "node-008",
      "label": "ABCL – Phase 2 efficacy win",
      "dimensions": {
        "time": "2025-01-28",
        "company": "ABCL",
        "eventType": "Phase 2 readout",
        "score": 0.82,
        "source": "Company PR",
        "impact": 83
      }
    },
    {
      "id": "node-009",
      "label": "ABCL – Strategic partnership",
      "dimensions": {
        "time": "2025-04-11",
        "company": "ABCL",
        "eventType": "Partnership",
        "score": 0.68,
        "source": "Business Wire",
        "impact": 61
      }
    },
    {
      "id": "node-010",
      "label": "ABCL – Follow-on financing",
      "dimensions": {
        "time": "2025-08-03",
        "company": "ABCL",
        "eventType": "Financing",
        "score": 0.52,
        "source": "SEC Filing",
        "impact": 48
      }
    },
    {
      "id": "node-011",
      "label": "ABCL – Phase 3 survival benefit",
      "dimensions": {
        "time": "2025-11-19",
        "company": "ABCL",
        "eventType": "Phase 3 readout",
        "score": 0.75,
        "source": "Company PR",
        "impact": 77
      }
    },
    {
      "id": "node-012",
      "label": "LENZ – EMA label expansion",
      "dimensions": {
        "time": "2024-09-07",
        "company": "LENZ",
        "eventType": "Regulatory",
        "score": 0.66,
        "source": "EMA",
        "impact": 64
      }
    },
    {
      "id": "node-013",
      "label": "LENZ – Autoimmune alliance",
      "dimensions": {
        "time": "2025-02-22",
        "company": "LENZ",
        "eventType": "Partnership",
        "score": 0.71,
        "source": "Company PR",
        "impact": 69
      }
    },
    {
      "id": "node-014",
      "label": "LENZ – Phase 2 biomarker data",
      "dimensions": {
        "time": "2025-05-30",
        "company": "LENZ",
        "eventType": "Phase 2 readout",
        "score": 0.59,
        "source": "Conference Abstract",
        "impact": 58
      }
    },
    {
      "id": "node-015",
      "label": "LENZ – Convertible financing",
      "dimensions": {
        "time": "2025-07-12",
        "company": "LENZ",
        "eventType": "Financing",
        "score": 0.45,
        "source": "Investor Call",
        "impact": 43
      }
    },
    {
      "id": "node-016",
      "label": "LENZ – FastTrack designation",
      "dimensions": {
        "time": "2025-10-09",
        "company": "LENZ",
        "eventType": "FastTrack",
        "score": 0.81,
        "source": "FDA",
        "impact": 85
      }
    },
    {
      "id": "node-017",
      "label": "VERU – Oncology co-development",
      "dimensions": {
        "time": "2024-12-02",
        "company": "VERU",
        "eventType": "Partnership",
        "score": 0.62,
        "source": "PR Newswire",
        "impact": 60
      }
    },
    {
      "id": "node-018",
      "label": "VERU – Safety update filed",
      "dimensions": {
        "time": "2025-03-14",
        "company": "VERU",
        "eventType": "Regulatory",
        "score": 0.54,
        "source": null,
        "impact": 50
      }
    },
    {
      "id": "node-019",
      "label": "VERU – Phase 3 survival data",
      "dimensions": {
        "time": "2025-06-25",
        "company": "VERU",
        "eventType": "Phase 3 readout",
        "score": 0.77,
        "source": "Conference Abstract",
        "impact": 82
      }
    },
    {
      "id": "node-020",
      "label": "VERU – Investor Q&A session",
      "dimensions": {
        "time": "2025-09-18",
        "company": "VERU",
        "eventType": null,
        "score": 0.38,
        "source": "Investor Call",
        "impact": 36
      }
    },
    {
      "id": "node-021",
      "label": "VERU – Breakthrough FastTrack",
      "dimensions": {
        "time": "2026-01-05",
        "company": "VERU",
        "eventType": "FastTrack",
        "score": 0.88,
        "source": "FDA",
        "impact": 90
      }
    },
    {
      "id": "node-022",
      "label": "PMN – Health Canada review",
      "dimensions": {
        "time": "2024-08-21",
        "company": "PMN",
        "eventType": "Regulatory",
        "score": 0.57,
        "source": "Health Canada",
        "impact": 55
      }
    },
    {
      "id": "node-023",
      "label": "PMN – Debt financing",
      "dimensions": {
        "time": "2024-12-15",
        "company": "PMN",
        "eventType": "Financing",
        "score": 0.49,
        "source": "Investor Call",
        "impact": 44
      }
    },
    {
      "id": "node-024",
      "label": "PMN – Manufacturing partner",
      "dimensions": {
        "time": "2025-04-04",
        "company": "PMN",
        "eventType": "Partnership",
        "score": 0.73,
        "source": "Company PR",
        "impact": null
      }
    },
    {
      "id": "node-025",
      "label": "PMN – Phase 2 cognitive data",
      "dimensions": {
        "time": "2025-07-27",
        "company": "PMN",
        "eventType": "Phase 2 readout",
        "score": 0.61,
        "source": "Conference Abstract",
        "impact": 59
      }
    },
    {
      "id": "node-026",
      "label": "PMN – Phase 3 enrollment milestones",
      "dimensions": {
        "time": "2025-11-08",
        "company": "PMN",
        "eventType": "Phase 3 readout",
        "score": 0.80,
        "source": "Company PR",
        "impact": 84
      }
    },
    {
      "id": "node-027",
      "label": "XBIO – FDA meeting minutes",
      "dimensions": {
        "time": "2024-07-11",
        "company": "XBIO",
        "eventType": "Regulatory",
        "score": 0.64,
        "source": "FDA",
        "impact": 62
      }
    },
    {
      "id": "node-028",
      "label": "XBIO – Manufacturing collaboration",
      "dimensions": {
        "time": "2024-10-29",
        "company": "XBIO",
        "eventType": "Partnership",
        "score": 0.55,
        "source": "Business Wire",
        "impact": 53
      }
    },
    {
      "id": "node-029",
      "label": "XBIO – Secondary offering",
      "dimensions": {
        "time": "2025-02-05",
        "company": "XBIO",
        "eventType": "Financing",
        "score": 0.36,
        "source": "SEC Filing",
        "impact": 32
      }
    },
    {
      "id": "node-030",
      "label": "XBIO – Phase 2 immune response",
      "dimensions": {
        "time": "2025-06-07",
        "company": "XBIO",
        "eventType": "Phase 2 readout",
        "score": 0.67,
        "source": "Company PR",
        "impact": 66
      }
    },
    {
      "id": "node-031",
      "label": "XBIO – Phase 3 efficacy trend",
      "dimensions": {
        "time": "2025-09-30",
        "company": "XBIO",
        "eventType": "Phase 3 readout",
        "score": 0.79,
        "source": "Conference Abstract",
        "impact": 81
      }
    },
    {
      "id": "node-032",
      "label": "QGEN – Diagnostics alliance",
      "dimensions": {
        "time": "2024-11-22",
        "company": "QGEN",
        "eventType": "Partnership",
        "score": 0.58,
        "source": "PR Newswire",
        "impact": 57
      }
    },
    {
      "id": "node-033",
      "label": "QGEN – FDA clearance",
      "dimensions": {
        "time": "2025-01-17",
        "company": "QGEN",
        "eventType": "Regulatory",
        "score": 0.63,
        "source": "FDA",
        "impact": 63
      }
    },
    {
      "id": "node-034",
      "label": "QGEN – Financing outlook updated",
      "dimensions": {
        "time": null,
        "company": "QGEN",
        "eventType": "Financing",
        "score": 0.47,
        "source": "Investor Deck",
        "impact": 45
      }
    },
    {
      "id": "node-035",
      "label": "QGEN – Phase 2 assay results",
      "dimensions": {
        "time": "2025-08-26",
        "company": "QGEN",
        "eventType": "Phase 2 readout",
        "score": 0.72,
        "source": "Conference Abstract",
        "impact": 70
      }
    },
    {
      "id": "node-036",
      "label": "QGEN – Phase 3 accuracy data",
      "dimensions": {
        "time": "2025-12-14",
        "company": "QGEN",
        "eventType": "Phase 3 readout",
        "score": 0.76,
        "source": "Company PR",
        "impact": 79
      }
    }
  ]
}
